Integra Lifesciences Holdings Corp (NASDAQ: IART)

Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives through innovative products. The company designs manufactures and sells medical technologies used in neurosurgery neurocritical care ENT wound care and regenerative therapies. It operates worldwide serving hospitals surgery centers and health care providers. Integra was the first to receive an FDA claim for regeneration of dermal tissue and remains a world leader in regenerative technology.

The company generates revenue primarily from the sale of its medical devices and biomaterial products. Approximately 70% of total revenue comes from the Codman Specialty Surgical segment which includes neurosurgical instruments dural repair products ICP monitoring systems and cranial stabilization devices. The Tissue Technologies segment contributes the remaining 30% of revenue through wound reconstruction regenerative tissue solutions and private label manufacturing. Integra distributes its products via a direct sales force and independent distributors across North America Europe Asia Pacific and Latin America.

The company operates through the following segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT).

• Codman Specialty Surgical: This segment provides neurosurgery neurocritical care and ENT products. It offers ultrasonic surgical aspirators ICP monitors dural graft matrices dural sealant systems cranial stabilization systems surgical headlamps reusable and disposable instruments and navigation systems for sinus procedures. The segment also supplies neuro access tools and neuro monitoring platforms for adult and pediatric patients.

• Tissue Technologies: This segment develops regenerative tissue products for wound reconstruction and private label. It uses bovine collagen bovine dermis porcine urinary bladder human amniotic tissue and resorbable synthetic mesh to treat burns chronic wounds hernia repair and nerve reinforcement. The segment also provides contract manufacturing services for other medical technology companies seeking custom biomaterial solutions.

Integra LifeSciences holds a leading position in neurosurgery where it is recognized as a global leader and ranks among the top three providers in the United States for precision specialty and general surgical instruments. The company is also a world leader in regenerative technology with the first FDA approved dermal regeneration template and a broad portfolio of biomaterial solutions. Its main competitors in the Codman Specialty Surgical segment include divisions of Medtronic Stryker Steris and B. Braun Medical. In the Tissue Technologies segment it faces competition from Smith & Nephew Organogenesis MiMedx Allergan Becton Dickinson and Axogen. Integra maintains its competitive edge through a deep sales and marketing organization continuous product innovation and strong procurement and manufacturing capabilities.

Integra sells its products to hospitals integrated health networks group purchasing organizations clinicians surgery centers and other health care providers. The company relies on a combination of direct sales representatives and independent distributors to reach these customers globally. No single customer accounts for more than ten percent of Integra’s consolidated revenue.